Published in J Pain Symptom Manage on July 01, 2002
Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol (2012) 3.26
Opioid prescription in Italy: new law, no effect. Lancet (2002) 2.01
High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer (2011) 1.65
Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract (2010) 1.53
CT-guided neurolytic splanchnic nerve block by an anterior approach. J Pain Symptom Manage (2002) 1.39
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain (2008) 1.04
Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage (2009) 1.00
Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI--Italian questionnaire for intense episodic pain. J Pain Symptom Manage (2012) 0.99
Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage (2004) 0.99
Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer (2004) 0.98
Peritoneal catheter for continuous drainage of ascites in advanced cancer patients. Support Care Cancer (2008) 0.97
Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage (2004) 0.97
Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage (2005) 0.96
The use of high doses of oxycodone in an acute palliative care unit. Am J Hosp Palliat Care (2010) 0.96
High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients. J Pain Symptom Manage (2008) 0.96
A model of acute symptom control unit: Pain Relief and Palliative Care Unit of La Maddalena Cancer Center. Support Care Cancer (2002) 0.96
Opioid escalation in patients with cancer pain: the effect of age. J Pain Symptom Manage (2006) 0.95
Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain (2007) 0.93
Controlled sedation for refractory symptoms in dying patients. J Pain Symptom Manage (2008) 0.91
Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin (2012) 0.91
Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage (2003) 0.91
Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manage (2007) 0.91
Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Oncology (2002) 0.90
Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage (2004) 0.90
Patients' and relatives' perceptions about intravenous and subcutaneous hydration. J Pain Symptom Manage (2005) 0.89
Gabapentin in painful ophthalmoplegia. J Pain Symptom Manage (2002) 0.89
Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage (2006) 0.87
Opioid-induced or pain relief-reduced symptoms in advanced cancer patients? Eur J Pain (2006) 0.87
Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer (2002) 0.87
How to use octreotide for malignant bowel obstruction. J Support Oncol (2004) 0.86
Incidence of chronic pain in patients with end-stage renal disease on dialysis. J Pain Symptom Manage (2005) 0.86
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin (2010) 0.85
Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med (2009) 0.85
The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin (2009) 0.85
Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol (2005) 0.84
An Italian survey on the attitudes in treating breakthrough cancer pain in hospice. Support Care Cancer (2010) 0.84
The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen. Clin J Pain (2010) 0.84
Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manage (2011) 0.84
Treatment strategies for cancer patients with breakthrough pain. Expert Opin Pharmacother (2009) 0.83
Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther (2009) 0.83
Breakthrough pain: on the road again. Eur J Pain (2009) 0.82
Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients. J Pain (2009) 0.82
Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage (2006) 0.82
Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manage (2003) 0.81
Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer patients with pain. Support Care Cancer (2005) 0.81
Outcome of opioid switching 4 weeks after discharge from a palliative care unit. Curr Med Res Opin (2011) 0.80
Local anesthetics for breakthrough pain in patients receiving intrathecal treatment for cancer pain management. Anesth Analg (2005) 0.80
Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer (2006) 0.80
The role of OROS hydromorphone in the management of cancer pain. Pain Pract (2009) 0.80
When the progression of disease lowers opioid requirement in cancer patients. Clin J Pain (2010) 0.79
Does pain intensity predict a poor opioid response in cancer patients? Eur J Cancer (2011) 0.79
Withdrawal acute psychosis after corticosteroid discontinuation. J Pain Symptom Manage (2007) 0.79
Emerging drugs for cancer-related pain. Support Care Cancer (2011) 0.79
The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients. Clin J Pain (2013) 0.78
Tracheal stent to repair tracheal laceration after a double-lumen intubation. Ann Thorac Surg (2012) 0.78
Surgical treatment of early breast cancer in day surgery. Chir Ital (2007) 0.78
The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study. Support Care Cancer (2010) 0.78
Video-thoracoscopic surgical pleurodesis in the management of malignant pleural effusion: the importance of an early intervention. J Pain Symptom Manage (2005) 0.77
Itraconazole-fentanyl interaction in a cancer patient. J Pain Symptom Manage (2002) 0.77
Localization of the sentinel lymph node in breast cancer: prospective comparison of vital staining and radioactive tracing methods. Chir Ital (2004) 0.77
Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumori (2002) 0.77
Refractory death rattle: deep aspiration facilitates the effects of antisecretory agents. J Pain Symptom Manage (2010) 0.77
Opioid switching and burst ketamine to improve the opioid response in patients with movement-related pain due to bone metastases. Clin J Pain (2009) 0.76
Prevalence of opioid-related dysuria in patients with advanced cancer having pain. Am J Hosp Palliat Care (2010) 0.76
Clarifications on oxycodone-naloxone combination in cancer pain management. Support Care Cancer (2012) 0.76